CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs.


Become a global leader actively involved in creating Canadian and international networks dedicated to advancing next-generation technologies that will bring more quickly better cures to patients.

Business Model

CQDM is a biopharmaceutical research consortium that funds innovation. We bring together world-class pharmaceutical corporations, several Canadian biotech companies, the best scientists from both the public and private sectors, as well as the Canadian and Quebec governments.
CQDM’s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. This approach leverages funds up to tenfold (each dollar invested in CQDM can generate up to 10 dollars in research), thereby allowing the biopharmaceutical research consortium to support research that could not otherwise be funded. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned.

A promising projects portfolio

Over $78 M raised

Since its foundation in 2008, our biopharmaceutical research consortium has funded innovation by raising over $78M in contributions from:

  • 12 of the largest pharmaceutical companies in the world: Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Janssen, Novartis Pharma Canada, Sanofi Canada, Servier Roche and Takeda;
  • The Ministère de l’Économie, de la Science et de l’Innovation (MESI) of the Government of Quebec;
  • The Business Led-Networks of Centres of Excellence (BL-NCE) program of the Government of Canada.

To date, CQDM has established 11 funding programs, launched 28 calls for proposals and more than 800 projects, for a total of over $805M in funding applications.

To date, CQDM boasts:

  • 64 outstanding research projects;
    • carried out by a network of 976 researchers, including 204 graduate and post-graduate students;
    • in 76 research institutions (40 public and 36 private);
    • engaging 120 mentors from CQDM’s pharmaceutical member companies;
    • for a total of $44M invested in R&D by CQDM.

Convincing results

The results to date speak for themselves, with technologies that accelerate drug discovery and generate significant socioeconomic benefits, including:

  • 31 successfully completed projects achieving 87% of deliverables;
  • A 73% integration rate in biopharmaceutical R&D;
  • CQDM pharmaceutical partners committing significant additional contributions to several research laboratories to further develop CQDM technologies;
  • technologies reaching maturity in 21 SMEs active in the life sciences sector;
  • launch of 10 start-ups in the life sciences sector;
  • creation of 697 new high-value jobs;
  • $41M in additional investments for researchers.